Skip to main content
. 2019 Jun 19;15(9):2066–2074. doi: 10.1080/21645515.2019.1616499

Figure 4.

Figure 4.

Pre-challenge LASV-specific neutralizing antibodies. (a) Specific, dose-dependent neutralization of LASV, but not VSV, pseudovirus by LASV GPC-specific monoclonal antibody 25.1C. (b) Pre-challenge NHP serum samples collected at weeks 0 and 6 post-immunization were measured for LASV pseudovirus neutralizing activity and neutralizing EPTs calculated as described in the methods.